{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:48:33Z","timestamp":1769640513503,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T00:00:00Z","timestamp":1397260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Tuberculosis (<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>) remains a major global health problem. In patients with rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>), the risk of reactivation of latent <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> infection (<jats:styled-content style=\"fixed-case\">LTBI<\/jats:styled-content>) is increased and treatment with tumour necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) antagonists further increases this risk. However, interpretation of results describing comparative <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> risk during therapy with different <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> antagonists is difficult. This is not only a result of different patient ethnic groups and background <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> rates, but also because of differing methods of data acquisition. This paper offers a critical appraisal of registry data pertaining to <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients treated with different anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> agents, focusing on methodological approaches that may limit the generalizability of findings or invalidate the direct comparison of <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> risk between different national registries. Underlying factors that can make data interpretation challenging are discussed, including differences in methods for <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> diagnosis or data collection and reporting, as well as background <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> risk. The introduction of special monitoring systems, such as prospective multinational registries, to strengthen surveillance and better quantify the extent of under\u2010reporting is required, especially in countries where the background <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> risk is high.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.12375","type":"journal-article","created":{"date-parts":[[2014,4,12]],"date-time":"2014-04-12T05:10:53Z","timestamp":1397279453000},"page":"716-724","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tuberculosis risk and anti\u2010tumour necrosis factor agents in rheumatoid arthritis: a critical appraisal of national registry data"],"prefix":"10.1111","volume":"17","author":[{"given":"Rossana","family":"Scrivo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, Rheumatology Sapienza University of Rome Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orlando","family":"Armignacco","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit Belcolle Hospital Viterbo Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,12]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization(2013)WHO Report 2013: Global Tuberculosis Report 2013. Available from URL:www.who.int\/tb\/publications\/global_report\/en."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00120908"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00028510"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.12.004"},{"key":"e_1_2_11_7_1","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona L","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"e_1_2_11_9_1","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong SS","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.791"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1214673"},{"key":"e_1_2_11_13_1","first-page":"6","article-title":"Tumour necrosis factor\u2010alpha and tuberculosis: guidance from the National TB Advisory Committee","volume":"101","author":"Kavanagh PM","year":"2008","journal-title":"Ir Med J"},{"key":"e_1_2_11_14_1","first-page":"77","article-title":"Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update","volume":"33","author":"Fonseca JE","year":"2008","journal-title":"Acta Reumatol Port"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"e_1_2_11_17_1","first-page":"620","article-title":"Screening for tuberculosis infection before the initiation of an anti\u2010TNF\u2010alpha therapy","volume":"137","author":"Beglinger C","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"e_1_2_11_19_1","unstructured":"National Institute for Health and Clinical Excellence 2011"},{"key":"e_1_2_11_20_1","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection \u2013 United States, 2010","volume":"59","author":"Mazurek GH","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_11_21_1","first-page":"S15","article-title":"Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety","volume":"29","author":"Favalli EG","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120165"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1586\/eci.11.6"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120688"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2049-6"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22808"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/506935"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20001215)19:23<3199::AID-SIM621>3.0.CO;2-Q"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03553.x"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066761"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21788"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta5160"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.12375","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.12375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:51:28Z","timestamp":1695477088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.12375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,12]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/1756-185X.12375"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.12375","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,12]]},"assertion":[{"value":"2014-04-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}